H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR)
Tweet Send to a Friend
H.C. Wainwright analyst Arthur He reiterated a Buy rating and $6.50 price target on Nektar Therapeutics (NASDAQ: NKTR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


